ArticleJCI insight2016
Profiling cancer testis antigens in non-small-cell lung cancer.
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 120 citations in OpenAlex.
- Sulforaphane Bioavailability and Chemopreventive Activity in Men Presenting for Biopsy of the Prostate Gland: A Randomized Controlled Trial.Nutrition and cancer · 2020Trial
- A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer.Scientific reports · 2019Trial
- Spatially resolved T cell receptor diversity mapping uncovers variability of the cancer immune microenvironment.EBioMedicine · 2026Article
- Article
- Vascular invasion-associated gene expression is detectable in pre-surgical biopsies of stage I lung adenocarcinoma.Nature communications · 2026Article
- EZHIP in Pediatric Brain Tumors: From Epigenetic Mimicry to Therapeutic Vulnerabilities.International journal of molecular sciences · 2026Review
- In situ mapping of activated PDGFRβ defines a prognostic discrepancy between histological subtypes of NSCLC.Cell communication and signaling : CCS · 2026Article
- Multi-cohort machine learning identifies a ferroptosis-linked prognostic signature in lung adenocarcinoma.Frontiers in bioinformatics · 2026Article
- Multi-omic profiling of squamous cell lung cancer identifies metabolites and related genes associated with squamous cell carcinoma.Molecular oncology · 2025Article
- Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer.Journal for immunotherapy of cancer · 2025Article
- Spatial distribution of tertiary lymphoid structures in the molecular and clinical context of non-small cell lung cancer.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Article
- RNAseqCovarImpute: a multiple imputation procedure that outperforms complete case and single imputation differential expression analysis.Genome biology · 2024Article
- Single-cell sequencing unveils extensive intratumoral heterogeneity of cancer/testis antigen expression in melanoma and lung cancer.Journal for immunotherapy of cancer · 2024Article
- Identification of a gene expression signature of vascular invasion and recurrence in stage I lung adenocarcinoma via bulk and spatial transcriptomics.bioRxiv : the preprint server for biology · 2024Article
- Genomic analysis of human brain metastases treated with stereotactic radiosurgery reveals unique signature based on treatment failure.iScience · 2024Article
- Review
- Article
- Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer.Molecular oncology · 2023Article
- Development of dendritic cell loaded MAGE-A2 long peptide; a potential target for tumor-specific T cell-mediated prostate cancer immunotherapy.Cancer cell international · 2023Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer testis antigens (CTAs) are of clinical interest as biomarkers and present valuable targets for immunotherapy. To comprehensively characterize the CTA landscape of non-small-cell lung cancer (NSCLC), we compared RNAseq data from 199 NSCLC tissues to the normal transcriptome of 142 samples from 32 different normal organs. Of 232 CTAs currently annotated in the Caner Testis Database (CTdatabase), 96 were confirmed in NSCLC. To obtain an unbiased CTA profile of NSCLC, we applied stringent criteria on our RNAseq data set and defined 90 genes as CTAs, of which 55 genes were not annotated in the CTdatabase, thus representing potential new CTAs. Cluster analysis revealed that CTA expression is histology dependent and concurrent expression is common. IHC confirmed tissue-specific protein expression of selected new CTAs (TKTL1, TGIF2LX, VCX, and CXORF67). Furthermore, methylation was identified as a regulatory mechanism of CTA expression based on independent data from The Cancer Genome Atlas. The proposed prognostic impact of CTAs in lung cancer was not confirmed, neither in our RNAseq cohort nor in an independent meta-analysis of 1,117 NSCLC cases. In summary, we defined a set of 90 reliable CTAs, including information on protein expression, methylation, and survival association. The detailed RNAseq catalog can guide biomarker studies and efforts to identify targets for immunotherapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.